Stamford announces positive results from Phase 2 Study of SP-002 in combination with 4-weeks of vismodegib in multi-lesional Basal Cell Carcinoma patients
Stamford has announced positive results for its ASN-002-003 multi-lesional clinical trial (NCT
04416516. Protocol No ASN-002-003) evaluating SP-002, an Adenovirus-5 replication
deficient vector encoding human Interferon- in combination with vismodegib (a Hedgehog
Pathway Inhibitor) in subjects presenting with multiple BCCs.
“We are very pleased with these positive results from the Phase 2 study demonstrating the
safety and efficacy of our gene therapy for patients with multiple nodular and superficial BCCs.
We are particularly excited that the histopathologic criteria, which would allow responsive
patients to be identified at screening and used for patient selection. This histopathologic
criterion was first noted in the ASN-002-001 clinical study and has now been successfully
reproduced in ASN-002-003. We believe this enables us to develop a useful treatment option
for patients with nodular BCC and addresses the important need for a non-surgical option for
those with BCCs in the H-zone or for those who are not ideal candidates for surgery.” Dr
Clement Leong (PhD), CEO of Stamford Pharmaceuticals